Amin Addetia
LightNews LightNews
aminaddetia.bsky.social
Amin Addetia
@aminaddetia.bsky.social
39 followers 58 following 0 posts
Senior Scientist at UW
viruses & antibodies
Posts Replies Media Videos
Reposted by Amin Addetia
veeslerlab.bsky.social
Delighted to share the peer-reviewed version of our article describing a prefusion-stabilized MARV GP vaccine immunogen and a best-in-class MARV neutralizing and protective antibody!

Led by @aminaddetia.bsky.social with @virbiotechnology.bsky.social

@hhmi.org

www.nature.com/articles/s41...
Potent neutralization of Marburg virus by a vaccine-elicited antibody - Nature
Nature - Potent neutralization of Marburg virus by a vaccine-elicited antibody
www.nature.com
November 12, 2025 at 4:20 PM
Reposted by Amin Addetia
veeslerlab.bsky.social
Our latest work on #COVID immunity and imprinting in humans.
Led by Ale Tortorici and Kaiti Sprouse with @aminaddetia.bsky.social and several others!

www.biorxiv.org/content/10.1...
Repeated COVID-19 vaccine boosters elicit variant-specific memory B cells in humans
The first exposure to a pathogen or an antigen profoundly impacts immune responses upon subsequent encounter with related pathogens. This immune imprinting explains that infection or vaccination with ...
www.biorxiv.org
October 21, 2025 at 3:42 AM
Reposted by Amin Addetia
veeslerlab.bsky.social
Outbreaks of Marburg virus (MARV) disease have been increasingly more frequent recently. Here we describe a prefusion-stabilized MARV GP and a best-in-class MARV neutralizing antibody!

Led by @aminaddetia.bsky.social with @virbiotechnology.bsky.social

@hhmi.org

www.biorxiv.org/content/10.1...
Potent neutralization of Marburg virus by a vaccine-elicited monoclonal antibody
Marburg virus (MARV) is a filovirus that causes a severe and often lethal hemorrhagic fever. Despite the increasing frequency of MARV outbreaks, no vaccines or therapeutics are licensed for use in hum...
www.biorxiv.org
May 18, 2025 at 8:40 PM
Reposted by Amin Addetia
veeslerlab.bsky.social
Delighted to share our most recent work on designing broadly protective sarbecovirus vaccines and defining the path forward for other coronaviruses.

Led by @aminaddetia.bsky.social

@hhmi.org

www.biorxiv.org/content/10.1...
Phylogeny-driven design of broadly protective sarbecovirus receptor-binding domain nanoparticle vaccines
Vaccines against emerging SARS-CoV-2 variants and sarbecoviruses with pandemic potential must elicit a robust humoral immune response in a population imprinted with the SARS-CoV-2 spike (S) protein. H...
www.biorxiv.org
May 14, 2025 at 2:21 PM
Reposted by Amin Addetia
veeslerlab.bsky.social
In these 2 papers, we show that two merbecovirus clades (HKU5 & MOW15-22, distantly related to MERS-CoV) independently evolved ACE2 receptor utilization, reshaping our understanding of coronavirus evolution

Led by Young-Jun Park on our side!

@hhmi.bsky.social

www.cell.com/cell/fulltex...
Molecular basis of convergent evolution of ACE2 receptor utilization among HKU5 coronaviruses
The family of coronaviruses known as merbecoviruses has generally been thought to use the host cell protein DPP4 for entry, but this study shows that the merbecovirus HKU5 can enter host cells of the ...
www.cell.com
February 7, 2025 at 4:12 PM
Reposted by Amin Addetia
veeslerlab.bsky.social
Here, we show that SARS-CoV-2 nsp1 inhibits translation in a wide range of mammalian cells from known hosts (deer, mink, cat, dog,...) & unveils the architecture of a Rhinolophus bat ribosome with mRNA channel obstructed by nsp1!

Led by Risako Gen
@hhmi.bsky.social

www.biorxiv.org/content/10.1...
SARS-CoV-2 nsp1 mediates broad inhibition of translation in mammals
SARS-CoV-2 nonstructural protein 1 (nsp1) promotes innate immune evasion by inhibiting host translation in human cells. However, the role of nsp1 in other host species remains elusive, especially in b...
www.biorxiv.org
January 16, 2025 at 10:21 PM